🚀We are thrilled to announce our participation in Vivalyx €5M seed round alongside Brightlands Venture Partners, TVF | TechVision Fonds, GOOSE Capital, and esteemed business angels such as Springboard Health Angels, Angel Invest, Andrej Henkler, and others.🚀 Congratulation to Andreas Schumacher, Benedict Doorschodt, René H. Tolba, Christian Bleilevens and the entire Vivalyx team! 💪 Press release: 🫀 https://lnkd.in/erBaMcUy
Arve Capital
Investment Management
We invest in seed and early stage technology companies in the area of health and well-being.
Info
Arve Capital is the venture capital arm of a German single family office with an investment focus on early-stage technology companies in the area of health and well-being. Based on the entrepreneurial roots in the healthcare sector, Arve Capital is a dedicated long-term partner for passionate founders on their mission to ensure and promote healthy lives.
- Branche
- Investment Management
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Heidelberg
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
Orte
-
Primär
Wegbeschreibung
Heidelberg, 69115, DE
Beschäftigte von Arve Capital
Updates
-
🎉More great news from Avelo! 🎉 After winning a €1.5M Eurostar grant in October, our portfolio company Avelo secures a new CHF 1.5M grant from Innosuisse. 🚀 The grant will drive the development of AveloCollect, a new breath sampling device aimed at improving the diagnosis of lower respiratory tract infections (LRTIs) 😮💨. Congratulations to Melanie, Tobias and the entire team! More: www.avelolife.com/news #breathanalytics #respiratoryinfections #MDx #moleculardiagnostics
-
-
We are happy to announce our participation in the seed round of IQONIC.AI alongside Brandenburg Kapital GmbH , YZR Capital and HEARTFELT_.(APX) https://lnkd.in/ehHt9gVz IQONIC.AI offers AI-based skin analysis as a SaaS solution to enable beauty brands and retailers to provide their customers with personalized product recommendations. Congratulations to Maria-Liisa Bruckert, Martin Pentenrieder and team on closing this seven-figure financing round! We are looking forward to support you on your journey to upgrade personalized hair and skin care. 🚀
IQONIC.AI: Siebenstellige Seed-Finanzierung für Berliner KI-Unternehmen
starting-up.de
-
Congratulations to Manuel Opitz, Ratko Petrovic, M.Sc., all Medical Co-Founders and the entire team of deepeye - preventing blindness on closing a 2.5 m€ seed round!🚀 Arve Capital is excited to join deepeye's mission alongside YZR Capital, Bayern Kapital, Springboard Health Angels to prevent 1 million additional people from blindness by 2030 by empowering ophthalmologists with AI-based optimal therapy prognosis. https://lnkd.in/d3gtfnpn 100 million people globally suffer from vision-threatening retinal diseases. A $13bn drug 💉👁️can stop patients from vision loss. Still, ⅔ of cases of blindness in EU US are due to these diseases like wet AMD. Deepeye provides an AI-based precision health platform that improves therapy outcomes by up to 6x by boosting: -Adherence & persistence from 38% to 78% (2x) -Real-world vision outcomes from 36% to 100% (3x) deepeye’s pre-clinical AI is used by pharma, payors, and providers’ associations to gain new insights into their therapy data. The company aims to launch it's clinical precision health platform to provide therapy decision support with 1 click at the Point-of-Care by 2024. Peter Mussinghoff, Albrecht Lommatzsch, Matthias Gutfleisch, Markus Feuerecker, Paul Kurz, Mathias Matusek, Autumn Lang, Tanja Berthues
-
-
Congratulations to our portfolio company Avelo and the entire team around Melanie Aregger and Tobias Broger for securing a research grant of €1.5M from Eurostars! https://lnkd.in/ehJ8Un94 #breathanalytics #respiratoryinfections #MDx #moleculardiagnostics
Avelo, VIVOLTA, and BLINK AG have won a Eurostars Eureka Network grant valued at €1.5M to develop a disposable breath collection device and a high-throughput diagnostic assay capable of screening multiple pathogens at the point-of-need 🎉 🎉 🎉 . The development project will span two years and lay the foundation for market launch in 2027. Using the new system, clinicians will be able to distinguish between viral and bacterial infections within 30 minutes of collecting the patient’s breath sample. The solution will be the world’s first breath-based system capable of fast, accurate, and specific diagnosis of lower respiratory tract infections. Visit our website on https://lnkd.in/ethAV_Td to learn more about this exciting project and synergistic consortium.
-